Previous Article | Next Article ![]()
Journal of Bacteriology, December 2008, p. 7693-7698, Vol. 190, No. 23
0021-9193/08/$08.00+0 doi:10.1128/JB.00853-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Laboratory of Molecular Microbiological Science, Faculty of Pharmaceutical Sciences, Hiroshima International University, Hiro-Koshingai, Kure, Hiroshima 737-0112,1 Department of Pharmacogenetics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan2
Received 23 June 2008/ Accepted 11 September 2008
|
|
|---|
|
|
|---|
TolC is a major OM channel in E. coli that plays an important role in the excretion of a wide range of molecules, including antibiotics (18, 25, 27), bile salts (3, 40, 45), organic solvents (1), enterobactin (4), several antibacterial peptides such as colicin V (11, 12) and microcin J25 (7), and also a large protein toxin, alpha-hemolysin (47, 48). Although TolC acts as a unique OM channel in these cases, various kinds of IM transporters and accessory proteins interact with TolC and enable E. coli to expel structurally diverse molecules. To date, it has been found that TolC can associate with at least 11 kinds of IM transporters and accessory proteins. They are AcrAB, AcrAD, AcrEF, MdtABC, MdtEF, EmrAB, EmrKY, MacAB, YojHI, CvaAB, and HlyBD. For instance, the AcrAB-TolC system functions as a major excretion apparatus for antibiotics, bile salts, and noxious organic solvents and provides intrinsic resistance to these compounds (1, 3, 18, 25, 27, 40, 45). CvaAB, YojHI, and HlyBD enable the bacterium to export proteinaceous factors such as colicin V, microcin J25, and alpha-hemolysin, respectively (7, 11, 12, 47, 48). Thus, TolC plays a central role in the extracellular transport of diverse molecules in cooperation with various kinds of translocators.
Yamanaka et al. and Foreman et al. found that TolC is also involved in the secretion of the heat-stable enterotoxins (STs; STI and STII) produced by enterotoxigenic E. coli (ETEC) (16, 50). Although in their primary structure these STs are quite different (32, 34, 44, 52), their maturation processes are similar. That is, these STs are synthesized as precursor proteins with an amino-terminal signal sequence and are translocated across the IM via the Sec machinery (16, 31, 51). After translocation, the toxins are released into the periplasm and folded to the mature forms via the actions of DsbA, a periplasmic disulfide oxidoreductase (9, 30, 49). The mature STs thus produced are ultimately transported from the periplasm into the milieu through the TolC channel (9, 50). This evidence indicates the TolC channel is also involved in the excretion of periplasmic substrates such as STs. However, it remains unclear how STs produced in the periplasm are moved to the TolC channel. In several known efflux systems containing TolC, the components construct a tripartite transport system as described above. We therefore presume that a certain transporter in cooperation with TolC recognizes the periplasmic ST molecules and leads them to the interior of the TolC channel.
In this study, we examined whether several distinct types of IM translocators and their accessory proteins, which are already known to function with TolC, participate in the translocation of STs from the periplasm to the exterior. The transporters examined in this study are AcrAB, AcrEF, MdtEF, EmrAB, EmrKY, MacAB, and YojHI. It is known that AcrAB, AcrEF, and MdtEF are RND (resistance nodulation cell division) family transporters, EmrAB and EmrKY are MF (major facilitator) superfamily transporters, and MacAB and YojHI are ABC (ATP-binding cassette) family transporters (7, 27, 29, 39). The results revealed that an ABC transporter, MacAB, was involved in the translocation of STII from the periplasm into the milieu but not in the translocation of STI. This is the first report about a factor engaged in the export of an ST from the periplasm to the exterior in cooperation with TolC.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Bacterial strains and plasmids used in this study
|
and was immediately followed by the addition of 1 ml of SOC medium (SOB medium containing 20 mM glucose). We then incubated the culture for 2 h at 37°C. A 100-µl aliquot of the cell suspension was spread onto LB agar containing kanamycin and incubated for 16 to 18 h at 37°C to select for kanamycin-resistant recombinants. |
View this table: [in a new window] |
TABLE 2. PCR primers designed for gene disruptionsa
|
Elimination of the antibiotic resistance gene.
To make multiple gene knockout (KO) mutants, we eliminated the kan gene on the chromosome introduced by the homologous recombination. We utilized pCP20, a temperature-sensitive plasmid that shows thermal induction of FLP (flip-out) recombinase (6). The kan replacement mutants were transformed with pCP20, and the transformants were selected at 30°C on LB agar containing both ampicillin and chloramphenicol, after which a few were colony purified once, nonselectively, at 43°C and then tested for loss of all antibiotic resistance. We confirmed the loss of kan on the chromosome by means of a PCR analysis using primers for the regions upstream and downstream of each target gene (Table 2). The deletion mutants thus obtained were used in the second direct mutation for the next target gene. Repeating these procedures, we made multiple KO mutants: BL21(DE3)
2-1,
2-2,
3,
4,
5,
6, and
7 (Table 1).
Pulse-chase experiment. The pulse-chase experiment using L-[35S]cysteine (ICN Biomedicals) was performed according to our previously described method (33, 50). After the pulse-chase period (pulse for 3 min, chase for 3 min), the culture was fractionated into culture supernatant and periplasmic fractions as described previously (33, 50). Both fractions were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), using a 20% acrylamide gel. Radiolabeled STs were visualized by autoradiography using BioMax MS X-ray film (Kodak).
Insertion of macAB into the plasmid pACYC184. The macAB gene was amplified from the chromosomal DNA of E. coli BL21(DE3) using two primers, MacAB-up (5'-AAAAGTGACAAGCTTCTGAGAGATTCA-3') and MacAB-down (5'-GCAGTCGCATAAAGCTTCTGTCTCATTGTG-3'). These primers cover the regions upstream and downstream of macAB, respectively. Both primers contain a HindIII site (underlined). The macAB gene amplified with these primers encompassed both the promoter and structural regions of the gene. The amplified gene fragments were digested with HindIII. The resulting gene fragments were inserted into a HindIII site of the plasmid pACYC184. The plasmid obtained was designated pACYC-MacAB (Table 1).
Sensitivity test. The sensitivity of cells to erythromycin was examined by halo assay on an LB agar plate using a Tridisk (Eiken, Japan). A drop of bacterial suspension (approximately 108 cells/ml) was spread on an LB agar plate. A Tridisk attached to three filters containing 0.5, 2.0, and 10.0 µg/ml of erythromycin was carefully placed onto the plate. The plate was allowed to incubate overnight at 37°C. We then observed the halo (growth inhibition zone) formed around each filter.
Immunoblotting against TolC. Preparation of the OM fraction and detection of the TolC band on the SDS-PAGE (12.5% acrylamide) gel by immunoblotting were performed as described previously (53). To detect TolC, an antiserum prepared by injecting a peptide (ELRKSAADRDAAFEK) conjugated with ovalbumin into rabbits was used. The generated immune complexes were detected with a chemiluminescence reagent (Amersham Biosciences, United Kingdom).
|
|
|---|
Secretion of STs in multiple KO mutants. Since all standard E. coli strains can release STs to the exterior when transformed with the plasmid containing the ST gene alone, we postulated that an intrinsic mechanism contributes to the secretory process. To date, it has been found that nine IM translocators and their accessory proteins, both encoded on the E. coli chromosome, can construct a tripartite transport system in cooperation with TolC. They are AcrAB, AcrAD, AcrEF, MdtABC, MdtEF, EmrAB, EmrKY, MacAB, and YojHI (7, 21, 27, 28). We therefore focused upon these transporters in this study.
We made multiple KO mutants (
1 to
7) derived from BL21(DE3) as shown in Table 1 and analyzed the extracellular secretion of STs in these mutants by conducting pulse-chase experiments. As shown in Fig. 1A, the amount of TolC in the OM was almost the same in all KO mutants, suggesting that these gene disruptions did not affect the production of TolC.
![]() View larger version (52K): [in a new window] |
FIG. 1. Secretion of STs from cells of E. coli BL21(DE3) and derivative deletion mutants. TolC in the OM of each mutant was detected by immunoblotting using anti-TolC antiserum (A). To examine the secretion of STs, a pulse-chase experiment was carried out as described in the text. The culture supernatant and periplasmic fractions were resolved by SDS-PAGE (20% acrylamide gel), and STs in the gels were detected by autoradiography. (B and C) Secretion of STI (B) and STII (C) from cells.
|
1 to
7) was efficiently secreted into the culture supernatant (lanes 3 to 10), and the amount of STI remaining in the periplasm was very small (lanes 13 to 20), as observed in the wild-type cells (lanes 2 and 12). This result indicates that deletion of the transporter genes did not affect the extracellular secretion of STI. We therefore conclude that the transporters encoded by these genes (AcrAB, AcrEF, EmrAB, EmrKY, MacAB, MdtEF, and YojHI) are not engaged in the secretion of STI.
In contrast, we also examined the secretion of STII in these mutant strains harboring pET11-STII. The results are shown in Fig. 1C. In both BL21(DE3) mutants
1 and
2-1, almost all the STII produced in the cells was released into the culture supernatant (lanes 3 and 4) and the amount remaining in the periplasm was very small (lanes 13 and 14), as observed with the wild-type strain (lanes 2 and 12). However, in the other mutants (
2-2 to
7), the extracellular secretion of STII was markedly disturbed (lanes 5 to 10) and a large amount remained in the periplasm (lanes 15 to 20). This result indicates that the translocation of STII from the periplasm to the exterior was largely decreased in these mutants. Since both macAB and yojHI genes were knocked out in all of these mutants, we speculate that either MacAB, YojHI, or both participate in the translocation of STII from the periplasm to the exterior.
Secretion of STs in the macAB::kan or yojHI::kan mutant.
To examine the involvement of MacAB and/or YojHI in the extracellular transportation of STII, a pulse-chase experiment was carried out using a single-gene-disrupted mutant, macAB::kan [BL21(DE3)
mac] or yojHI::kan [BL21(DE3)
yoj]. In these mutants, the immunoblotting analysis clearly revealed that the production of TolC was not affected by the mutation of the target gene (Fig. 2A).
![]() View larger version (38K): [in a new window] |
FIG. 2. Effects of disruption of the macAB and yojHI genes on translocation of STs from the periplasm to the exterior. TolC in the OM of each mutant was detected by immunoblotting using anti-TolC antiserum (A). To examine the secretion of STs, a pulse-chase experiment using cells harboring the indicated plasmid(s) was performed as described in the text. The culture supernatant and periplasmic fractions were resolved by SDS-PAGE (20% acrylamide gel), and STs in the gels were detected by autoradiography. (B and C) Secretion of STI (B) and STII (C) from cells.
|
2-2 harboring pET-STII (Fig. 2C, lanes 5 and 11). Disruption of yojHI, however, did not affect the secretion of STII (Fig. 2C, lanes 3 and 9). These results indicate that MacAB is closely involved in the translocation of STII from the periplasm into the culture supernatant.
Restoration of STII secretion in the macAB::kan mutant by the introduction of pACYC-MacAB.
To confirm the participation of MacAB in the transportation of STII from the periplasm to the exterior, we introduced the compatible plasmid pACYC184 containing macAB (pACYC-MacAB) into BL21(DE3)
mac harboring pET-STII. First, we estimated the expression of MacAB from pACYC-MacAB. SDS-PAGE (12.5% acrylamide gel) of the sonicated cell preparation revealed that both MacA and MacB were expressed in the mutant transformed with pACYC-MacAB (Fig. 3A, lane 2) but not in the mutant without the plasmid (Fig. 3A, lane 1). Next, we assessed the activity of MacAB expressed from pACYC-MacAB. Since MacAB participates in the excretion of macrolides such as erythromycin, we performed a sensitivity test using a Tridisk containing erythromycin. In this test, we used the mutant
3 because AcrAB also functions in the excretion of macrolides. As shown in Fig. 3B (lane 2), the mutant
3 was highly sensitive to erythromycin. In contrast, the mutant
3 transformed with pACYC-MacAB became resistant to erythromycin (Fig. 3B, lane 3) as observed with the wild type (Fig. 3B, lane 1), suggesting that MacAB expressed from pACYC-MacAB was actually functional.
![]() View larger version (37K): [in a new window] |
FIG. 3. Functional analysis of MacAB expressed from pACYC-MacAB. (A) SDS-PAGE (12.5% acrylamide gel) analysis of the sonicated cell preparation obtained from cells harboring the indicated plasmid. The positions of molecular mass markers are shown on the left. The arrows on the right indicate the positions of MacA and MacB. (B) Bioassay for erythromycin efflux by the MacAB expressed from pACYC-MacAB. A sensitivity test using a Tridisk containing erythromycin (0.5, 2.0, and 10 µg/ml) was performed as described in the text.
|
mac was completely restored by the introduction of pACYC-MacAB (lane 4) and the amount of STII remaining in the periplasm was markedly decreased (lane 10). Similarly, the secretion of STII from the mutant
2-2 was also restored by the introduction of pACYC-MacAB (Fig. 2C, lanes 6 and 12). These results strongly support that MacAB contributes to the translocation of STII from the periplasm to the exterior, although it does not participate in the secretion of STI. Thus, the secretory processes from the periplasm to the outside differ between STI and STII. It has been reported that MacAB is an ABC transporter that collaborates with TolC (14, 15). Although MacAB was first recognized as a transporter that participates in the excretion of macrolides such as erythromycin (15), the results of our study suggest that it can transport other substrates, including STII. For Salmonella enterica serovar Typhimurium, Nishino et al. recently reported that deletion of macAB attenuated virulence (26). It is, therefore, likely that MacAB also functions as a specific export system in E. coli that is closely related to bacterial pathogenicity.
How does MacAB engage in the export of STII in E. coli? Although further study is needed to fully answer this question, MacAB must be able to capture the substrates from the periplasm and translocate them into the center of the tunnel formed by TolC, because the STII precursor is released into the periplasm, where it is converted into the mature toxin (30). Our previous study indicated that STII was localized in the periplasmic fraction, not in the IM fraction containing MacAB, when the toxin was produced in a tolC-deficient strain (53). It is therefore likely that the interaction of STII with MacAB may be weak or transient, although the interaction must occur specifically. In the efflux of some β-lactams through an RND family transporter, AcrB, it has been reported that drugs in the periplasm might be collected in the central cavity through vestibules that are opened to the periplasm (19, 20, 43) and the adaptor protein AcrA might play an important role in the transfer of energy provided by AcrB to the TolC channel to be opened (2, 17). Furthermore, in the MacAB system, Tikhonova et al. recently reported that the adaptor protein MacA stimulates the ATPase activity of MacB and acts as a functional subunit of the MacB transporter (46). It is, therefore, likely that similar molecular mechanisms, as expected in the AcrAB-TolC system, are involved in the transportation of the periplasmic STII molecules through the MacAB-TolC apparatus.
In gram-negative bacteria, six different secretion systems (types I to VI) have been identified as specific to extracellular proteins (5, 13, 36, 38, 41, 42). The type II secretion system usually functions in the transport of products that have been released and have matured in the periplasm. In this system, the periplasmic products are translocated across the OM via a multimeric protein complex called the secreton (10, 37). In the secretion of STII, however, the periplasmic toxin molecules are transported to the exterior via a distinct intrinsic transport system, MacAB-TolC, although they are released into the periplasm through the Sec machinery as seen with the type II secretory process. At this point, we should emphasize that STII is secreted via a unique pathway different from that for other protein toxins.
In conclusion, we propose a schematic model for the secretion of STs (Fig. 4) in which MacAB recognizes and transports periplasmic STII but not STI into the entrance of the TolC channel and the STII molecules are ultimately released to the exterior through the channel. However, we have not found any evidence for the interaction of STII with MacAB. Several molecular approaches will be required to resolve this process. Elucidation of the tertiary structure of MacAB may also help to consider the molecular mechanism behind this secretory process. Further research is in progress in our laboratory.
![]() View larger version (22K): [in a new window] |
FIG. 4. Schematic model of secretion of STs to the exterior.
|
Published ahead of print on 19 September 2008. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»